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Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovas-
cular age-related macular degeneration (nv-AMD).Methods. Forty-seven eyes of 47 patients with nv-AMD, and corrected distance
visual acuity (CDVA) logMAR 0.7 or better, undergoing intravitreal injections of ranibizumab, were enrolled into this prospective
study. Visual function was assessed using a range of psychophysical tests, while mean foveal thickness (MFT) was determined by
optical coherence tomography (OCT). Results. Groupmean (±sd) MFT reduced significantly from baseline (233 (±59)) to exit (205
(±40)) (𝑃 = 0.001). CDVA exhibited no change between baseline and exit visits (𝑃 = 0.48 and 𝑃 = 0.31, resp.). Measures of visual
function that did exhibit statistically significant improvements (𝑃 < 0.05 for all) included reading acuity, reading speed, mesopic
and photopic contrast sensitivity (CS), mesopic and photopic glare disability (GD), and retinotopic ocular sensitivity (ROS) at
all eccentricities. Conclusion. Eyes with nv-AMD undergoing intravitreal ranibizumab injections exhibit improvements in many
parameters of visual function. Outcome measures other than CDVA, such as CS, GD, and ROS, should not only be considered in
the design of studies investigating nv-AMD, but also in treatment and retreatment strategies for patients with the condition.
1. Introduction
Choroidal neovascularisation (CNV), amanifestation of neo-
vascular age-related macular degeneration (nv-AMD), is
characterised by the growth of abnormal choroidal blood ves-
sels, which penetrate Bruch’s membrane and sometimes the
retinal pigment epithelium (RPE) [1]. If left untreated, the
leakage results in subretinal and/or retinal scarring, with con-
sequential and irreversible loss of central vision [2].
Vascular endothelial growth factor (VEGF), a diffusible
cytokine, is an important factor promoting CNV in AMD [3,
4]. Clinical trials have confirmed the efficacy of ranibizumab
(Lucentis, Genentech), an inhibitor of VEGF, over laser
therapy with intravenous Visudyne and over observation
alone [5, 6].
Currently, corrected distance visual acuity (CDVA), a
measure of the resolving power of the eye at high contrast [7],
represents the standard vision-related outcome measure for
management of nv-AMD. However, CDVA is not a true
reflection of daily visual experience in a world with few visual
stimuli at such high levels of contrast, suggesting that perhaps
othermeasures of visual functionmay bemore appropriate in
assessing visual performance and experience in patients with
nv-AMD [8, 9].
Techniques alternative to CDVA, and relevant to nv-
AMD, include (but are not restricted to): contrast sensitivity
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(CS) [10, 11]; glare disability (GD) [12]; retinotopic ocular sen-
sitivity (ROS) [13–16]; preferential hyperacuity [17]; reading
performance [18–20]; and subject-reported experience by
validated questionnaire [21–23].
In this study, we investigated visual performance, and its
response to treatment, in patients with nv-AMD undergoing
treatment with intravitreal ranibizumab, and with baseline
CDVA of logMAR 0.7 or better. Considering that baseline
CDVA levels have been shown to influence the extent to
which CDVA improves following treatment [24, 25], we
sought to explore the impact of treatment on visual function
in this subset of subjects and investigate if there are observ-
able improvements/changes when psychophysical parame-
ters other than CDVA are employed as outcome measures.
2. Methods
2.1. Patients. Suitability for inclusion in the study was con-
firmed by an ophthalmologist, in compliance with the follow-
ing inclusion criteria: the study eye must be suffering from
active nv-AMD (fluid and/or cysts in the retina resulting
from blood vessels that are actively leaking, as observed on
fundus fluorescein angiography (FFA)) and be scheduled to
commence, recommence, or continue a course of intravitreal
ranibizumab; have a baseline CDVA of logMAR 0.7 or better;
and exhibit no visually important ocular comorbidity. All
patients were recruited from the Institute of Eye Surgery,
Whitfield Clinic, Waterford. Exclusion criteria included a
history of diabetes mellitus. In cases where both eyes were
being treated, the eye with the better CDVA was selected for
the study. Ethics approval was granted by the Dublin Institute
of Techonology Ethics Committee, and informed consentwas
secured from each subject. The research was conducted in
accordance with the principles of the Declaration of Helsinki.
Visual function and optical coherence tomography
(OCT) data were collected at baseline, and at monthly
intervals (midway between monthly ranibizumab injections)
within the 12 month study period. For the purposes of
statistical analysis, baseline and exit study visit data were
used. An exit visit was defined as the patient’s final study visit
(two weeks after the preceding and final intravitreal injection
in the study). Subjects exited the study either when the study
period came to an end (𝑛 = 20; after a maximum follow-up
of 11 months; some of these patients may have continued
with further intravitreal injections of ranibizumab following
closure of the study), when treatment was discontinued
on clinical grounds (𝑛 = 23; in these cases it was deemed,
clinically, that maximum realisable benefits of treatment had
been acheived), when the patient was unable to continue in
the study for unrelated health reasons (𝑛 = 2), or when the
patient elected to discontinue his/her participation in the
study (𝑛 = 2).
A diagnosis of nv-AMD was made by a retinal specialist
on the basis of clinical examination, OCT, and FFA. The
standard regime of treatment (following initial diagnosis)
included three consecutive monthly injections, followed by
monthly evaluation for further treatment. Subsequent injec-
tions were administered based on signs of lesion activity on
OCT and FFA. This protocol has been previously described
[26], and typically upon resolution of fluid and/or cysts
(determined by OCT), one more intravitreal injection of
ranibizumab was administered and two weeks following
that intraocular injection, FFA was repeated. Where lesion
inactivity was angiographically confirmed, treatment was
discontinued.
2.2. Visual Performance. Corrected distance visual acuitywas
measured for the study eye monocularly, and with the
patient’s best subjective refraction using the logMAR chart
provided by a letter chart (Test Chart 2000 PRO:Thomson
Software Solutions, Hertfordshire, England) at a testing
distance of 4m.
CS was measured using the sine wave grating-based
Functional Vision Analyser (Stereo Optical Co., Inc—Chica-
go, USA). Testing was performed under mesopic (3 candela
per square metre [cd/m2]) and photopic (85 cd/m2) condi-
tions. This test was repeated in a similar manner under mes-
opic and photopic conditions but in the presence of an inbuilt
circumferential LEDglare source (1 lux formesopic and 10 lux
for photopic glare testing) to assess GD [27].
ROS was measured by microperimetry (Microperimeter
MP 1; Nidek Technologies Srl, Albignasego, Italy) adhering
to a previously described protocol [28]. Microperimetry
assesses macular function by examining the light differential
threshold at specific points on the retina, under direct visuali-
sation of the fundus.The patient was instructed to fixate a red
cross spanning three degrees fromfixation, for the duration of
the test. The examination pattern comprised 21 stimuli, pre-
sented undermesopic background illumination of 1.27 cd/m2
(4 asb). The stimulus size was Goldmann III (26 minutes of
arc), of white colour and of 200msec presentation duration.
Stimulus intensity ranged from 20 dB (dimmest [4 asb]) to
0 dB (brightest [400 asb]); an increase of 1 dB equates to 0.1
log reduction in stimulus intensity (asb). Thresholds were
determined using a 4-2 linear staircase strategy. ROS was cal-
culated for three areas: fixation (one stimulus); within central
5 degrees (including fixation) using an average of nine stim-
uli; and within 16 degrees of fixation (average of 21 stimuli).
Reading speed and near visual acuity (LogRAD [log
reading acuity]) weremeasuredwith anEnglish version of the
standardised Radner reading chart adhering to a previously
described protocol [29].
Every effort was made to minimise any learning effects
that may potentially influence psychophysical outcomes,
which included: careful explanation of each task, demonstra-
tions, test cards and/or trial runs where possible (at baseline),
and the exclusion of any unreliable data.
2.3. Assessment of Retinal Thickness. Optical coherence
tomography (OCT) was performed using a Topcon 3DOCT-
1000 (version 3.01, Mark I; Topcon Corporation, Tokyo,
Japan). The central 1mm mean foveal thickness (MFT) was
obtained from typical EDTRS (Early Treatment Diabetic
Retinopathy Study) macular thickness maps [30].The central
foveal thicknesswas defined as the distance between the inner
and outer boundaries of the scanned image, identified using
a validated internal algorithm, and did not include any fluid
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under the RPE. Mean foveal volume (MFV) was determined
in a similar fashion.
2.4. Statistical Analysis. Descriptive statistics were calculated
for all measured variables, including demographic, ocular,
psychophysical, and morphological data. Visual acuity rating
scores [31] were used for the statistical analysis of CDVAdata.
Statistical analysis was performed using the software package
PASW Statistics 18.0 (IBM Corp., Somers, NY, USA).
Baseline and exit visit measures were compared using
the paired-samples t-test. Correlations between observed
changes inMFT (andMFV) and observed changes in psycho-
physical measures (between baseline and exit study visits)
following serial anti-VEGF therapy were investigated using
Pearson correlations. Power analysis, for the sample size
of 43 subjects (following dropouts), yielded the following
results: for detecting a correlation of 0.5, the power of a
sample of this size is 0.94; for detecting a change of half a
standard deviation on a paired t test, the power is 0.89. Tests
were 2-sided in all analyses and the 5% level of significance
was used throughout, without adjustment for multiple tests.
We were not in favour of Bonferroni adjustment as we felt
it was too severe and may result in failure to reject null
hypotheses where rejection is warranted (i.e., it leads to
increased likelihood of Type II statistical errors).
3. Results
Forty-seven patients (47 study eyes)met the inclusion criteria
and were recruited into this study. Of these, 31 were already
undergoing treatment when recruited (mean (±sd) and range
of duration of prior treatment: 7 (±5) and 1–20months, resp.).
Eight of the 47 study patients were concurrently undergoing
serial intravitreal ranibizumab treatment in their fellow eye,
at enrolment. Beyond baseline, 43 patients continued in
the study, and the mean (±sd) number of visits for these
subjects was 6 (±2.6), with a range of 2–10 study visits (three
subjects had only two study visits). A total of 248 injections
of ranibizumab were administered to the study eyes over the
course of the investigation. The mean (±sd) and range of the
number of injections per patient was 5.4 (±2.8) and 1–10,
respectively, over the course of the study.
Baseline measurements were obtained 1-2 days prior
to the first injections (of that course of injections) in the
16 participants who were commencing or recommencing
treatment, one of whom did not continue beyond baseline.
This subgroup (𝑛 = 15) will be henceforth termed “Subgroup
A”. We anticipated that data in Subgroup A (as a result of the
recent (re)activation of nv-AMD in this subgroup), might
differ from study eyes where serial intravitreal treatment was
already underway, particularly since it has been shown that
the greatest improvements in vision are typically obtained
in the first three months of treatment [25, 32] and therefore
warranted separate analysis.
The results of tests to investigate which of the measured
parameters exhibited significant change over the course of the
study period are reported in Table 1. Of note, therewas no sta-
tistically significant change in CDVA for the study group (𝑃 =
0.480), or SubgroupA (𝑃 = 0.387), between baseline and exit.
Relationships between observed changes in MFT and
observed changes in parameters of visual function for the
study group and Subgroup A are displayed in Table 2.
4. Discussion
The purpose of this study was to evaluate outcome measures
for patients with nv-AMD undergoing intravitreal ranibi-
zumab therapy. Over the course of the study, MFT and
MFV decreased in response to treatment, consistent with
previous studies [26, 33, 34]. Parameters of visual function
that improved for the study group and Subgroup A included
reading speed (at best baseline LogRad value), mean reading
speed, CS under mesopic conditions at low and high spatial
frequencies, CS under photopic conditions at high spatial
frequencies, GD under mesopic conditions for low and high
spatial frequencies, GD under photopic conditions at low and
high spatial frequencies, and ROS within the central 5 and
central 16 degrees of fixation.
Mean CDVA did not improve significantly over the
course of the investigation for the study group or SubgroupA.
We believe this finding is attributable to our inclusion criteria
and to the short period of follow-up in this study. Other
studies have shown that poor baseline CDVA is associated
with a greater benefit of treatment in terms of this outcome
measure [24, 25], and this observation is consistent with the
findings of Williams and Blyth, who reported no significant
improvement in CDVA in patients with nv-AMD in patients
where baseline CDVA was 6/12 (logMAR 0.3) or better [35].
Given that, in the current study, all study eyes had baseline
CDVA of logMAR 0.7 or better (indeed, 42 of the 43 eyes
had baseline CDVA of logMAR 0.6 or better), and given the
“ceiling effect” previously reported [24, 25, 35], it is perhaps
unsurprising that we did not observe statistically significant
improvement in CDVA in our study, especially in light of the
short period of follow-up.
A review [36] has concluded that CS is an importantmea-
sure of visual function in patientswithAMD, based on studies
that have shown that, when compared with visual acuity, CS
better relates to the ability to perform tasks accurately and
efficiently, to discriminate between objects [37] and to judge
distances [38]. Also, GD is a clinically important problem in
AMD and impacts adversely on mobility performance [39].
In this study, there were observed improvements in CS and
GD, for a range of spatial frequencies, under both mesopic
and photopic conditions, for the entire study group and for
Subgroup A.
A progressive improvement of ROS in response to ranibi-
zumab therapy for nv-AMD, as far as 24months following the
initiation of treatment and in spite of stabilisation of visual
acuity after six months, has been previously demonstrated
[13]. In the current study, ROS, within the central 5 degrees
and within the central 16 degrees, improved significantly for
the study group and for Subgroup A, whereas ROS at fixation
improved significantly only when the entire study group was
considered. Microperimetry examines the light differential
threshold at the retina and depends on the intactness of
photoreceptors, whereas visual acuity is a measure of the
minimum angle of spatial resolution and depends largely
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Table 1: Psychophysical data for study eyes in the entire study group and Subgroup A, between baseline and exit study visits.
Variable
Entire group Subgroup A
Baseline exit P value Baseline exit P value
mean (±sd) mean (±sd) mean (±sd) mean (±sd)
CDVA 88 (9) 89 (10) 0.480 89 (12) 91 (13) 0.387
logRAD 0.33 (0.20) 0.28 (0.22) 0.032∗ 0.24 (0.18) 0.19 (0.19) 0.139
Reading speed 85 (28) 103 (46) 0.019∗ 85 (26) 118 (56) 0.037∗
Mean reading speed 136 (36) 146 (42) 0.005∗∗ 148 (28) 166 (36) 0.005∗∗
CS (mesopic)†
Frequency (cpd)
1.5 19.47 (10.1) 30.22 (21.00) 0.003∗∗ 20.30 (12.15) 39.43 (26.12) 0.008∗∗
3 28.93 (19.72) 42.02 (34.04) 0.004∗∗ 32.47 (24.01) 53.13 (33.87) 0.036∗
6 11.26 (9.78) 15.91 (17.32) 0.002∗∗ 10.43 (9.04) 10.14 (6.35) 0.070
12 4.09 (1.17) 4.88 (2.27) <0.005∗∗ 3.80 (0.77) 6.27 (3.35) 0.001∗∗
18 1.98 (0.15) 2.37 (1.25) <0.005∗∗ 1.93 (0.26) 3.07 (1.98) 0.001∗∗
CS (photopic)†
Frequency (cpd)
1.5 21.99 (13.83) 27.27 (18.91) 0.082 19.51 (11.11) 23.32 (14.91) 0.347
3 35.05 (23.68) 47.63 (30.12) 0.005∗∗ 40.00 (30.72) 61.07 (32.54) 0.020∗
6 19.56 (19.28) 28.44 (30.98) 0.001∗∗ 16.14 (16.75) 18.43 (15.90) 0.221
12 5.72 (4.00) 10.16 (15.29) <0.005∗∗ 7.40 (6.53) 19.47 (23.08) 0.025∗
18 2.49 (2.59) 3.58 (4.01) <0.005∗∗ 2.33 (1.59) 6.53 (5.82) 0.016∗
GD (mesopic)†
Frequency (cpd)
1.5 11.10 (7.88) 18.76 (15.03) 0.002∗∗ 12.40 (9.79) 27.87 (17.80) 0.019∗
3 16.47 (12.63) 29.28 (23.67) <0.005∗∗ 17.93 (14.80) 42.13 (30.51) 0.001∗∗
6 7.51 (6.02) 11.49 (11.71) <0.005∗∗ 6.00 (0.00) 7.00 (2.58) 0.134
12 4.02 (0.77) 4.70 (2.89) <0.005∗∗ 3.80 (0.77) 6.00 (4.72) 0.001∗∗
18 1.98 (0.15) 2.09 (0.43) <0.005∗∗ 1.93 (0.26) 2.27 (0.70) <0.005∗∗
GD (photopic)†
Frequency (cpd)
1.5 19.94 (12.38) 24.50 (14.79) 0.090 19.02 (13.31) 21.54 (13.27) 0.377
3 35.16 (25.82) 47.33 (33.20) <0.005∗∗ 43.13 (30.86) 67.67 (39.65) 0.039∗
6 19.04 (19.46) 28.42 (31.20) 0.001∗∗ 15.25 (14.22) 18.50 (19.24) 0.069
12 5.84 (5.96) 7.86 (9.21) <0.005∗∗ 7.53 (9.21) 13.80 (13.66) 0.022∗
18 2.40 (1.68) 3.63 (4.05) <0.005∗∗ 2.73 (2.63) 6.67 (5.83) 0.021∗
Mean ROS (dB)
Fixation 8.56 (5.91) 10.20 (5.71) 0.026∗ 8.36 (7.32) 11.64 (6.72) 0.056
Central 5∘ 9.63 (4.83) 11.18 (4.48) 0.003∗∗ 9.27 (6.46) 12.34 (5.17) 0.013∗
Central 16∘ 11.03 (4.49) 12.11 (4.00) 0.005∗∗ 10.32 (5.51) 12.55 (4.42) 0.017∗
OCT
MFT (𝜇m) 233 (59) 205 (40) 0.001∗∗ 275 (64) 208 (25) 0.002∗∗
MFV (𝜇m3) 0.18 (0.05) 0.16 (0.03) <0.005∗∗ 0.22 (0.05) 0.16 (0.02) 0.002∗∗
Abbreviations: reading speed (at best baseline LogRad value); wpm:words perminute;mean reading speed (for range of LogRad values); CS: contrast sensitivity;
mesopic: under mesopic conditions; cpd: cycles per degree; photopic: under photopic conditions; GD: glare disability; ROS: retinotopic ocular sensitivity; dB:
decibel; OCT: optical coherence tomography; MFT: mean foveal thickness; MFV: mean foveal volume; —: change was not significant.
Note: The P values reported are for the paired 𝑡 test (or the corresponding nonparametric test when the data distribution was non-normal).
∗Significant improvement at the 0.05 level (2 tailed).
∗∗Significant improvement at the 0.01 level (2 tailed).
†The statistical tests were based on log-transformed data.
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Table 2: Correlations between observed changes in mean foveal
thickness and observed changes in other parameters for the entire
study group and Subgroup A.
Variable Entire group Subgroup A
r P value r P value
CDVA −0.311∗ 0.042† −0.569∗ 0.027
ROS fixation −0.411∗∗ 0.008 −0.500 0.069
ROS central 5∘ −0.592∗∗ <0.001 −0.611∗ 0.020
ROS central 16∘ −0.536∗∗ <0.001 −0.554∗ 0.040
logRAD 0.182 0.242 0.505 0.055
Reading speed 0.105 0.501 0.537 0.039∗
Mean reading speed −0.259 0.307 0.033 0.908
LogCSmesopic 1.5cpd −0.122 0.440 0.133 0.651
LogCSmesopic 3cpd −0.073 0.645 −0.058 0.843
LogCSmesopic 6cpd −0.091 0.569 0.193 0.508
LogCSmesopic 12cpd −0.005 0.973 0.459 0.098
LogCSmesopic 18cpd −0.041 0.797 0.327 0.254
LogCSphotopic 1.5cpd 0.001 0.997 0.066 0.823
LogCSphotopic 3cpd −0.087 0.586 −0.086 0.770
LogCSphotopic 6cpd 0.018 0.910 −0.022 0.939
LogCSphotopic 12cpd −0.165 0.296 0.000 0.999
LogCSphotopic 18cpd −0.147 0.352 0.260 0.369
LogGDmesopic 1.5cpd −0.334∗ 0.031 −0.167 0.569
LogGDmesopic 3cpd −0.344∗ 0.026 −0.206 0.481
LogGDmesopic 6cpd −0.108 0.494 0.018 0.951
LogGDmesopic 12cpd 0.001 0.997 0.418 0.137
LogGDmesopic 18cpd −0.348∗ 0.024 −0.246 0.397
LogGDphotopic 1.5cpd 0.166 0.294 0.313 0.277
LogGDphotopic 3cpd 0.157 0.322 0.488 0.077
LogGDphotopic 6cpd −0.065 0.683 −0.125 0.671
LogGDphotopic 12cpd −0.208 0.187 0.078 0.792
LogGDphotopic 18cpd −0.220 0.161 0.140 0.634
Abbreviations: CDVA: corrected-distance visual acuity; ROS: retinotopic
ocular sensitivity; CS: contrast sensitivity; mesopic/photopic: under mesop-
ic/photopic conditions; cpd: cycles per degree; GD: glare disability.
∗Correlation significant at the 0.05 level (2 tailed).
∗∗Correlation significant at the 0.01 level (2 tailed).
†Removal of one outlier.
on the transparency of the ocular media [40]. Intuitively,
therefore, one would expect that measures of ROS are more
appropriate than CDVA when attempting to correlate func-
tion andmorphological changes at themacula, for conditions
such as AMD, which is consistent with the findings of the
current study. A recent study explored the relationships
between macular thickness, CDVA, and ROS in patients
previously treated with ranibizumab for nv-AMD and who
were now in the maintenance phase of therapy [41]. In
brief, intravitreal ranibizumab was administered if CDVA
and/or OCT was indicative of active disease. On this basis,
and at the study outset, sixteen of 21 eyes were classified
“unstable”, therefore requiring further intravitreal anti-VEGF
therapy. The remaining five were deemed “stable” and were
not administered any further intravitreal injections during
the study. Although eyes in both groups maintained visual
acuity over the study period, those in the “unstable” group
exhibited no significant change in ROS over the period
of investigation. However, eyes that were deemed “stable”
did exhibit a statistically significant decrease in mean ROS
during the study period, indicating that eyeswith stable visual
acuity and absence of intravitreal fluid may still exhibit a
deterioration of visual function reflected inmeasures of ROS,
which may be an indicator of subclinical CNV activity.
Given the importance of OCT in the diagnosis and
decision-to-treat/decision-to-discontinue treatment in cases
of nv-AMD, the relationships between observed changes in
MFT and observed changes in the psychophysical parame-
ters over the course of the study were analysed. Although
there was a significant correlation between observed changes
in MFT and observed changes in CDVA (which, notably,
became non-significant with the removal of an outlier) and
also with observed changes in GD under mesopic conditions
at low and high spatial frequencies, the strongest such associ-
ation was with observed change in ROS, both at fixation, but
more robustly, within the central 5 and 16 degrees of fixation.
It appears, therefore, that ROS may have an important, but
yet to be fully understood, role to play in the monitoring
of patients with nv-AMD undergoing serial intravitreal anti-
VEGF therapy.
For the study group and Subgroup A, a significant
improvement in reading speed was observed between base-
line and exit visits over the course of the study, but this
observed improvement did not correlate with a change in
CDVA. Such a disparity has been previously observed by
Frennesson et al., who suggested that a change in CDVA does
not necessarily relate to a change in near vision [42].
In an attempt to achieve best outcomes without overtreat-
ing patients with nv-AMD, the posology for intravitreal
ranibizumab for this condition has recently been revised
(http://www.medicines.ie/medicine/11837/SPC/Lucentis+
10mg+ml+Solution+for+Injection/#POSOLOGY).This revi-
sion of posology was informed by the evolving body of lit-
erature since the publication of the phase III MARINA and
ANCHOR trials, where monthly injections were given for
a period of two years. In brief, it is now recommended that
monthly injections are given until best CDVA is achieved
and maintained for three consecutive injections, when
interruption of treatment is recommended with monthly
monitoring. Where a deterioration in CDVA (defined as a
loss of five letters), attributable to activity of nv-AMD, is
observed, recommencement of treatment is recommended
under the same regime. In light of this revised posology,
however, the results of our study strongly suggest that
CS-guided or ROS-guided re-treatments are likely to be
more sensitive indicators of functional deterioration, and
would, therefore, prompt recommencement of treatment at
an earlier stage than would a deterioration in CDVA, thereby
reducing the risk of irrecoverable loss of central vision.
5. Conclusion
This study has demonstrated improvements in many param-
eters of visual function in eyes with nv-AMD undergoing
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monthly intravitreal ranibizumab injections. Outcome mea-
sures other than CDVA, such as CS, GD, and ROS, should
not only be considered in the design of studies investigating
nv-AMD, but also in treatment and retreatment strategies for
patients with the condition.
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